Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)

Opportunity snapshot. This Grants.gov announcement - Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional) - is cataloged under number PAR-25-296 and tied to CFDA assistance listing 93.121;93.172;93.307;93.313;93.350;93.846;93.855;93.859;93.865, posted by National Institutes of Health. Grants.gov currently shows the opportunity as open, first posted on December 11, 2024. The funding category is Discretionary, delivered as a cooperative agreement.

Award economics. The award range on file is Up to $650,000. The agency has projected $650,000 in total estimated funding for this announcement. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.

Deadline and action path. Applications close on October 19, 2027 - roughly 447 days from today. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.